Theresa Robb's questions to Agios Pharmaceuticals Inc (AGIO) leadership • Q2 2025
Question
Theresa Robb from Scotiabank requested more detail on the prescriber base for the initial thalassemia launch and how the company plans to manage care variability between academic and community settings.
Answer
CCO Tsveta Milanova explained that due to established ICD-10 codes, they have clear data on where patients are treated. While most transfusion-dependent patients are in academic centers, the company has proactively engaged community hematologists who manage many non-transfusion-dependent patients with disease education to prepare for the launch.